The specific objective of this contract will be to provide the Investigational Drug Branch (IDB), CTEP, DCT, NCI, with Phase I clinical evaluations of investigational new drugs which are developed through the DCT Linear Array and are sponsored to the Food and Drug Administration (FDA) under an IND held by DCT. The objective of Phase I studies is to provide the parameters and characteristics of drug toxicity, the maximally tolerated dose, and a recommended Phase II dose.
| Raber, M N; Adams, F; Kavanagh, J et al. (1987) Phase I trial of caracemide using bolus and infusion schedules. Cancer Treat Rep 71:349-52 |
| Spitzer, G; Valdivieso, M; Farha, P et al. (1986) I.v. melphalan in carcinoma of the lung: effect of cyclophosphamide priming on hematopoietic toxicity. Cancer Treat Rep 70:449-53 |
| Ajani, J A; Dimery, I; Chawla, S P et al. (1986) Phase II studies of homoharringtonine in patients with advanced malignant melanoma;sarcoma;and head and neck, breast, and colorectal carcinomas. Cancer Treat Rep 70:375-9 |
| Kavanagh, J J; Stringer, C A; Copeland, L J et al. (1986) Phase II trial of fludarabine in patients with epithelial ovarian cancer. Cancer Treat Rep 70:425-6 |
| Legha, S S; Tenney, D M; Krakoff, I R (1986) Phase I study of taxol using a 5-day intermittent schedule. J Clin Oncol 4:762-6 |
| Chiuten, D F; Umsawasdi, T; Dhingra, H M et al. (1985) Phase II clinical trial of diaziquone in bronchogenic carcinoma. Cancer Treat Rep 69:921-2 |
